Interaction of human brain acetylcholinesterase with cyclophosphamide: A molecular modeling and docking study

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 7, 2011, Pages 845-848

  Shakil, Shazi ^a   Khan, Rosina ^b   Tabrez, Shams ^a   Alam, Qamre ^a   Jabir, Nasimudeen R ^a   Sulaiman, Mansour I ^a   Greig, Nigel H ^c   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b ALIGARH MUSLIM UNIVERSITY   (India)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Cyclophosphamide; Docking; Enzyme inhibition; Human brain acetylcholinesterase; Hydrophobic interactions; Modeling

Indexed keywords

ACETYLCHOLINESTERASE; AMINO ACID; CARBON; CYCLOPHOSPHAMIDE;

ARTICLE; ATOM; BRAIN; ENZYME INHIBITION; HYDROPHOBICITY; MOLECULAR DOCKING; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; SOLVATION; X RAY CRYSTALLOGRAPHY;

EID: 81155153976     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711798072365     Document Type: Article

References (28)

1. Silman, I.; Sussman, J.L. Acetylcholinesterase: how is structure related to function? Chem. Biol. Interact., 2008, 175(1-3), 3-10.
2. Darvesh, S.; Hopkins, D.A.; Geula, C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci., 2003a, 4(2), 131-138.
3. Silman, I.; Sussman, J.L. Acetylcholinesterase: 'classical' and 'nonclassical' functions and pharmacology. Curr. Opin. Pharmacol., 2005, 5(3), 293-302.
4. Munoz-Delgado, E.; Montenegro, M.F.; Campoy, F.J.; MoralNaranjo, M.T.; Cabezas-Herrera, J.; Kovacs, G.; Vidal, C.J. Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types. FEBS J., 2010, 277(21), 4519-4529.
5. Howland, R.H. Alternative drug therapies for dementia. J. Psychosoc. Nurs. Ment. Health Serv., 2011, 49(5), 17-20.
6. Darreh-Shori, T.; Soininen, H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr. Alzheimer Res., 2010, 7(1), 67-73.
7. Mehndiratta, M.M.; Pandey, S.; Kuntzer, T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst. Rev., 2011, 2, CD006986.
8. Nunes, B. The use of cholinesterases in ecotoxicology. Rev. Environ. Contam. Toxicol., 2011, 212, 29-59.
9. Campe, P.C.; Harvey, R.A. In: Lippincott's Illustrated Reviews: Pharmacology; Mucel, M.J; Gertner, S. B. and Perper, M. M., Eds.; J.B. Lippincott Company: New York, 1993, p. 350.
10. Emadi, A.; Jones, R.J.; Brodsky, R.A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol., 2009, 6(11), 638-647.
11. Cabanillas, F. Front-line management of diffuse large B cell lymphoma. Curr. Opin. Oncol., 2010, 22(6), 642-645.
12. Spring, P.J.; Spies, J.M. Myasthenia gravis: options and timing of immunomodulatory treatment. BioDrugs., 2001, 15(3), 173-183.
13. Gold, R.; Hohlfeld, R.; Toyka, K.V. Progress in the treatment of myasthenia gravis. Ther. Adv. Neurol. Disord., 2008, 1(2), 36-51.
14. Stephenson, J.; Czepulkowski, B.; Hirst, W.; Mufti, G.J. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk. Res., 1996, 20, 235-241.
15. Kamal, M.A.; Reale, M.; Al-Jafari, A.A. Multiple approaches to analyze the data for rat brain acetylcholinesterase inhibition by cyclophosphamide. Neurochem. Res., 2010, 35(10), 1501-1509.
16. Kamal, M.A. Dual temperature model for the estimation of energetics parameters for acetylcholinesterase inhibition by cyclophosphamide. Biochem. Mol. Biol. Int., 1997, 43(3), 571-581.
17. Al-Jafari, A.A.; Kamal, M.A.; Alhomida, A.S. Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide. J. Enzyme Inhib., 1997, 11(4), 275-283.
18. Zhou, H.; Zhou, Y. Distance-scaled, finite ideal-gas reference state improves structure-derived potentials of mean force for structure selection and stability prediction. Protein Sci., 2002, 11(11), 2714-2726.
19. Zhang, C.; Liu, S., Zhou, Y. Accurate and efficient loop selections by the DFIRE-based all-atom statistical potential. Protein Sci., 2004, 13(2), 391-399.
20. Sussman, J.L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine binding protein. Science, 1991, 253(5022), 872-879.
21. Darvesh, S.; Walsh, R.; Kumar, R.; Caines, A.; Roberts, S.; Magee, D.; Rockwood, K.; Martin, E. Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis. Assoc. Disord., 2003b, 17(2), 117-126.
22. Al-Jafari, A.A.; Kamal, M.A.; Greig, N.H.; Alhomida, A.S.; Perry, E.R. Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine phenserine. Biochem. Biophys. Res. Commun., 1998, 248(1), 180-185.
23. Pepeu, G.; Giovannini, M.G. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res., 2009, 6 (2), 86-96.
24. Xu, Y.; Colletier, J.P.; Weik, M.; Jiang, H.; Moult, J.; Silman, I.; Sussman, J.L. Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics. Biophys. J., 2008, 95(5), 2500-2511.
25. Shakil, S.; Khan, A.U. Interaction of 2009 CTX-M variants with drugs and inhibitors: a molecular modelling and docking study. J. Proteomics Bioinform., 2010, 3, 130-134.
26. Pang, Y.P.; Kozikowski, A.R. Prediction of the binding site of 1-benzyl-4-[(5,6-di- methoxy-l-indanon-2-yl)methyl]piperidine in acetyl- cholinesterase by docking studies with the SYSDOC program. J. Computer-Aided Mol Design., 1994, 8, 683-693.
27. Genka, S.; Deutsch, J.; Stahle, P.L.; Shetty, U.H.; John, V.; Robinson, C.; Rapoport, S.I.; Greig, N.H. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol., 1990, 27(1), 1-7.
28. Greenblatt, H.M.; Dvir, H.; Silman, I.; Sussman, J.L. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J. Mol. Neurosci., 2003, 20(3), 369-383.